Idiopathic multicentric Castleman disease (iMCD) is a poorly understood hematologic disorder
involving cytokine-induced polyclonal lymphoproliferation, systemic inflammation, and …

Castleman disease (CD), a heterogeneous group of disorders that share morphological
features, is divided into unicentric CD and multicentric CD (MCD) according to the clinical …

… The predictive value was validated in an independent set of 197 patients with iMCD from
The International Castleman Disease Consortium. The proposed novel model is valuable for …

… We discover that CXCL13 is one of the most upregulated proteins in iMCD patient sera
relative to healthy donors. We also identify and validate CXCL13 as an early indicator of …

Castleman disease (CD) describes a heterogeneous group of hematologic disorders that
share characteristic lymph node histopathology. Patients of all ages present with either a …

… multicentric Castleman disease with JAK1/2 inhibition’ and ’Discovery and validation
of a novel subgroup and therapeutic target in idiopathic multi- centric Castleman disease 

… idiopathic multicentric Castleman disease with JAK1/2 inhibition” and “Discovery and validation
of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease.” …

Castleman disease (CD) represents a group of rare, heterogeneous and poorly understood
disorders that share characteristic histopathological features. Unicentric CD (UCD) typically …

… Asn666Ser were validated by targeted deep … Castleman Disease Collaborative Network
(CDCN) for their excellent work on accelerating researches and treatment for Castleman disease…

… Castleman disease from our prior study. Therefore, 3 groups of patients were compared:
those with Castleman disease … For further validation, we analyzed the correlation between the …